 | • レポートコード：MRC2Q12-19167 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、腎臓がん標的治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 腎臓がん標的治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 腎臓がん標的治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 腎臓がん標的治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの腎臓がん標的治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の腎臓がん標的治療の売上および2028年までの予測に焦点を当てています。 腎臓がん標的治療のグローバル主要企業には、Merck、Novartis、Pfizer、Roche、Amgen、Aveo Pharmaceuticals、Exelixis、Bayer、Eisai、Wyethなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 腎臓がん標的治療市場は、タイプとアプリケーションによって区分されます。世界の腎臓がん標的治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 チロシンキナーゼ阻害剤、mTOR阻害剤、EGFR阻害剤、抗VEGFモノクローナル抗体 【アプリケーション別セグメント】 腎細胞癌、腎骨盤癌、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 腎臓がん標的治療製品概要 - タイプ別市場（チロシンキナーゼ阻害剤、mTOR阻害剤、EGFR阻害剤、抗VEGFモノクローナル抗体） - アプリケーション別市場（腎細胞癌、腎骨盤癌、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の腎臓がん標的治療販売量予測2017-2028 - 世界の腎臓がん標的治療売上予測2017-2028 - 腎臓がん標的治療の地域別販売量 - 腎臓がん標的治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別腎臓がん標的治療販売量 - 主要メーカー別腎臓がん標的治療売上 - 主要メーカー別腎臓がん標的治療価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（チロシンキナーゼ阻害剤、mTOR阻害剤、EGFR阻害剤、抗VEGFモノクローナル抗体） - 腎臓がん標的治療のタイプ別販売量 - 腎臓がん標的治療のタイプ別売上 - 腎臓がん標的治療のタイプ別価格 ・アプリケーション別市場規模（腎細胞癌、腎骨盤癌、その他） - 腎臓がん標的治療のアプリケーション別販売量 - 腎臓がん標的治療のアプリケーション別売上 - 腎臓がん標的治療のアプリケーション別価格 ・北米市場 - 北米の腎臓がん標的治療市場規模（タイプ別、アプリケーション別） - 主要国別の腎臓がん標的治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの腎臓がん標的治療市場規模（タイプ別、アプリケーション別） - 主要国別の腎臓がん標的治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の腎臓がん標的治療市場規模（タイプ別、アプリケーション別） - 主要国別の腎臓がん標的治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の腎臓がん標的治療市場規模（タイプ別、アプリケーション別） - 主要国別の腎臓がん標的治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの腎臓がん標的治療市場規模（タイプ別、アプリケーション別） - 主要国別の腎臓がん標的治療市場規模（トルコ、サウジアラビア） ・企業情報 Merck、Novartis、Pfizer、Roche、Amgen、Aveo Pharmaceuticals、Exelixis、Bayer、Eisai、Wyeth ・産業チェーン及び販売チャネル分析 - 腎臓がん標的治療の産業チェーン分析 - 腎臓がん標的治療の原材料 - 腎臓がん標的治療の生産プロセス - 腎臓がん標的治療の販売及びマーケティング - 腎臓がん標的治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 腎臓がん標的治療の産業動向 - 腎臓がん標的治療のマーケットドライバー - 腎臓がん標的治療の課題 - 腎臓がん標的治療の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Kidney Cancer Targeted Therapy estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Kidney Cancer Targeted Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Kidney Cancer Targeted Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Kidney Cancer Targeted Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Kidney Cancer Targeted Therapy include Merck, Novartis, Pfizer, Roche, Amgen, Aveo Pharmaceuticals, Exelixis, Bayer and Eisai, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Kidney Cancer Targeted Therapy companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Kidney Cancer Targeted Therapy market. Further, it explains the major drivers and regional dynamics of the global Kidney Cancer Targeted Therapy market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Merck
Novartis
Pfizer
Roche
Amgen
Aveo Pharmaceuticals
Exelixis
Bayer
Eisai
Wyeth
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Kidney Cancer Targeted Therapy Segment by Type
Tyrosine Kinase Inhibitors
mTOR Inhibitors
EGFR Inhibitors
Anti-VEGF Monoclonal Antibody
Kidney Cancer Targeted Therapy Segment by Application
Renal Cell Cancer
Renal Pelvis Cancer
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Kidney Cancer Targeted Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Kidney Cancer Targeted Therapy market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Kidney Cancer Targeted Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Kidney Cancer Targeted Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Kidney Cancer Targeted Therapy revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Kidney Cancer Targeted Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Kidney Cancer Targeted Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck, Novartis, Pfizer, Roche, Amgen, Aveo Pharmaceuticals, Exelixis, Bayer and Eisai, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Kidney Cancer Targeted Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer Targeted Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kidney Cancer Targeted Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer Targeted Therapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Tyrosine Kinase Inhibitors
1.2.3 mTOR Inhibitors
1.2.4 EGFR Inhibitors
1.2.5 Anti-VEGF Monoclonal Antibody
1.3 Market by Application
1.3.1 Global Kidney Cancer Targeted Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Renal Cell Cancer
1.3.3 Renal Pelvis Cancer
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Kidney Cancer Targeted Therapy Market Perspective (2017-2028)
2.2 Kidney Cancer Targeted Therapy Growth Trends by Region
2.2.1 Kidney Cancer Targeted Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Kidney Cancer Targeted Therapy Historic Market Size by Region (2017-2022)
2.2.3 Kidney Cancer Targeted Therapy Forecasted Market Size by Region (2023-2028)
2.3 Kidney Cancer Targeted Therapy Market Dynamics
2.3.1 Kidney Cancer Targeted Therapy Industry Trends
2.3.2 Kidney Cancer Targeted Therapy Market Drivers
2.3.3 Kidney Cancer Targeted Therapy Market Challenges
2.3.4 Kidney Cancer Targeted Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer Targeted Therapy Players by Revenue
3.1.1 Global Top Kidney Cancer Targeted Therapy Players by Revenue (2017-2022)
3.1.2 Global Kidney Cancer Targeted Therapy Revenue Market Share by Players (2017-2022)
3.2 Global Kidney Cancer Targeted Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kidney Cancer Targeted Therapy Revenue
3.4 Global Kidney Cancer Targeted Therapy Market Concentration Ratio
3.4.1 Global Kidney Cancer Targeted Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Targeted Therapy Revenue in 2021
3.5 Kidney Cancer Targeted Therapy Key Players Head office and Area Served
3.6 Key Players Kidney Cancer Targeted Therapy Product Solution and Service
3.7 Date of Enter into Kidney Cancer Targeted Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer Targeted Therapy Breakdown Data by Type
4.1 Global Kidney Cancer Targeted Therapy Historic Market Size by Type (2017-2022)
4.2 Global Kidney Cancer Targeted Therapy Forecasted Market Size by Type (2023-2028)
5 Kidney Cancer Targeted Therapy Breakdown Data by Application
5.1 Global Kidney Cancer Targeted Therapy Historic Market Size by Application (2017-2022)
5.2 Global Kidney Cancer Targeted Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Kidney Cancer Targeted Therapy Market Size (2017-2028)
6.2 North America Kidney Cancer Targeted Therapy Market Size by Type
6.2.1 North America Kidney Cancer Targeted Therapy Market Size by Type (2017-2022)
6.2.2 North America Kidney Cancer Targeted Therapy Market Size by Type (2023-2028)
6.2.3 North America Kidney Cancer Targeted Therapy Market Share by Type (2017-2028)
6.3 North America Kidney Cancer Targeted Therapy Market Size by Application
6.3.1 North America Kidney Cancer Targeted Therapy Market Size by Application (2017-2022)
6.3.2 North America Kidney Cancer Targeted Therapy Market Size by Application (2023-2028)
6.3.3 North America Kidney Cancer Targeted Therapy Market Share by Application (2017-2028)
6.4 North America Kidney Cancer Targeted Therapy Market Size by Country
6.4.1 North America Kidney Cancer Targeted Therapy Market Size by Country (2017-2022)
6.4.2 North America Kidney Cancer Targeted Therapy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Kidney Cancer Targeted Therapy Market Size (2017-2028)
7.2 Europe Kidney Cancer Targeted Therapy Market Size by Type
7.2.1 Europe Kidney Cancer Targeted Therapy Market Size by Type (2017-2022)
7.2.2 Europe Kidney Cancer Targeted Therapy Market Size by Type (2023-2028)
7.2.3 Europe Kidney Cancer Targeted Therapy Market Share by Type (2017-2028)
7.3 Europe Kidney Cancer Targeted Therapy Market Size by Application
7.3.1 Europe Kidney Cancer Targeted Therapy Market Size by Application (2017-2022)
7.3.2 Europe Kidney Cancer Targeted Therapy Market Size by Application (2023-2028)
7.3.3 Europe Kidney Cancer Targeted Therapy Market Share by Application (2017-2028)
7.4 Europe Kidney Cancer Targeted Therapy Market Size by Country
7.4.1 Europe Kidney Cancer Targeted Therapy Market Size by Country (2017-2022)
7.4.2 Europe Kidney Cancer Targeted Therapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer Targeted Therapy Market Size (2017-2028)
8.2 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Type
8.2.1 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Kidney Cancer Targeted Therapy Market Share by Type (2017-2028)
8.3 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Application
8.3.1 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Kidney Cancer Targeted Therapy Market Share by Application (2017-2028)
8.4 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Region
8.4.1 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Kidney Cancer Targeted Therapy Market Size (2017-2028)
9.2 Latin America Kidney Cancer Targeted Therapy Market Size by Type
9.2.1 Latin America Kidney Cancer Targeted Therapy Market Size by Type (2017-2022)
9.2.2 Latin America Kidney Cancer Targeted Therapy Market Size by Type (2023-2028)
9.2.3 Latin America Kidney Cancer Targeted Therapy Market Share by Type (2017-2028)
9.3 Latin America Kidney Cancer Targeted Therapy Market Size by Application
9.3.1 Latin America Kidney Cancer Targeted Therapy Market Size by Application (2017-2022)
9.3.2 Latin America Kidney Cancer Targeted Therapy Market Size by Application (2023-2028)
9.3.3 Latin America Kidney Cancer Targeted Therapy Market Share by Application (2017-2028)
9.4 Latin America Kidney Cancer Targeted Therapy Market Size by Country
9.4.1 Latin America Kidney Cancer Targeted Therapy Market Size by Country (2017-2022)
9.4.2 Latin America Kidney Cancer Targeted Therapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer Targeted Therapy Market Size (2017-2028)
10.2 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Type
10.2.1 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Kidney Cancer Targeted Therapy Market Share by Type (2017-2028)
10.3 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Application
10.3.1 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Kidney Cancer Targeted Therapy Market Share by Application (2017-2028)
10.4 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Country
10.4.1 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Kidney Cancer Targeted Therapy Introduction
11.1.4 Merck Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.1.5 Merck Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Kidney Cancer Targeted Therapy Introduction
11.2.4 Novartis Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.2.5 Novartis Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Kidney Cancer Targeted Therapy Introduction
11.3.4 Pfizer Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.3.5 Pfizer Recent Developments
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Kidney Cancer Targeted Therapy Introduction
11.4.4 Roche Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.4.5 Roche Recent Developments
11.5 Amgen
11.5.1 Amgen Company Details
11.5.2 Amgen Business Overview
11.5.3 Amgen Kidney Cancer Targeted Therapy Introduction
11.5.4 Amgen Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.5.5 Amgen Recent Developments
11.6 Aveo Pharmaceuticals
11.6.1 Aveo Pharmaceuticals Company Details
11.6.2 Aveo Pharmaceuticals Business Overview
11.6.3 Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Introduction
11.6.4 Aveo Pharmaceuticals Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.6.5 Aveo Pharmaceuticals Recent Developments
11.7 Exelixis
11.7.1 Exelixis Company Details
11.7.2 Exelixis Business Overview
11.7.3 Exelixis Kidney Cancer Targeted Therapy Introduction
11.7.4 Exelixis Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.7.5 Exelixis Recent Developments
11.8 Bayer
11.8.1 Bayer Company Details
11.8.2 Bayer Business Overview
11.8.3 Bayer Kidney Cancer Targeted Therapy Introduction
11.8.4 Bayer Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.8.5 Bayer Recent Developments
11.9 Eisai
11.9.1 Eisai Company Details
11.9.2 Eisai Business Overview
11.9.3 Eisai Kidney Cancer Targeted Therapy Introduction
11.9.4 Eisai Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.9.5 Eisai Recent Developments
11.10 Wyeth
11.10.1 Wyeth Company Details
11.10.2 Wyeth Business Overview
11.10.3 Wyeth Kidney Cancer Targeted Therapy Introduction
11.10.4 Wyeth Revenue in Kidney Cancer Targeted Therapy Business (2017-2022)
11.10.5 Wyeth Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer